Monopar Therapeutics Inc. Earnings Per Share, Basic and Diluted
Monopar Therapeutics Inc. (MNPR) reported Earnings Per Share, Basic and Diluted of -$0.19 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-12
- Monopar Therapeutics Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.19.
- Monopar Therapeutics Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.21.
- Monopar Therapeutics Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.20.
- Monopar Therapeutics Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.17.
- Monopar Therapeutics Inc. earnings per share, basic and diluted for fiscal 2021 was -$0.73.
- Monopar Therapeutics Inc. earnings per share, basic and diluted for fiscal 2020 was -$0.58.
- Monopar Therapeutics Inc. earnings per share, basic and diluted for fiscal 2019 was -$0.45.
- Monopar Therapeutics Inc. earnings per share, basic and diluted for fiscal 2018 was -$0.35.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 3 month as first filed | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | -$0.19 10-Q · filed 2022-05-12 | -$0.41 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$0.60 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$0.77 derived: net income ÷ weighted average shares · filed 2023-11-09 | |
| 2021-12-31 | -$0.21 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$0.41 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$0.57 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$0.73 10-K · filed 2022-03-24 | |
| 2021-09-30 | -$0.20 10-Q · filed 2021-11-12 | -$0.36 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$0.52 10-Q · filed 2021-11-12 | -$0.70 derived: net income ÷ weighted average shares · filed 2022-11-10 | |
| 2021-06-30 | -$0.17 10-Q · filed 2021-08-12 | -$0.32 10-Q · filed 2021-08-12 | -$0.51 derived: net income ÷ weighted average shares · filed 2022-08-11 | -$0.65 derived: net income ÷ weighted average shares · filed 2022-08-11 | |
| 2021-03-31 | -$0.16 10-Q · filed 2022-05-12 | -$0.34 derived: net income ÷ weighted average shares · filed 2022-05-12 | -$0.49 derived: net income ÷ weighted average shares · filed 2022-05-12 | -$0.63 derived: net income ÷ weighted average shares · filed 2022-05-12 | |
| 2020-12-31 | -$0.19 derived: net income ÷ weighted average shares · filed 2022-03-24 | -$0.33 derived: net income ÷ weighted average shares · filed 2022-03-24 | -$0.47 derived: net income ÷ weighted average shares · filed 2022-03-24 | -$0.58 10-K · filed 2022-03-24 | |
| 2020-09-30 | -$0.15 10-Q · filed 2021-11-12 | -$0.28 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$0.39 10-Q · filed 2021-11-12 | -$0.52 derived: net income ÷ weighted average shares · filed 2021-11-12 | |
| 2020-06-30 | -$0.14 10-Q · filed 2021-08-12 | -$0.24 10-Q · filed 2021-08-12 | -$0.37 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$0.45 derived: net income ÷ weighted average shares · filed 2021-11-12 | |
| 2020-03-31 | -$0.10 10-Q · filed 2021-05-13 | -$0.23 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$0.31 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$0.41 derived: net income ÷ weighted average shares · filed 2021-11-12 | |
| 2019-12-31 | -$0.13 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$0.21 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$0.31 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$0.45 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$0.08 10-Q · filed 2020-11-12 | -$0.18 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$0.32 10-Q · filed 2020-11-12 | -$0.42 derived: net income ÷ weighted average shares · filed 2020-11-12 | |
| 2019-06-30 | -$0.10 10-Q · filed 2020-08-06 | -$0.25 10-Q · filed 2020-08-06 | -$0.34 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$0.41 derived: net income ÷ weighted average shares · filed 2020-11-12 | |
| 2019-03-31 | -$0.15 10-Q · filed 2020-05-07 | -$0.24 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$0.31 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$0.38 derived: net income ÷ weighted average shares · filed 2020-11-12 | |
| 2018-12-31 | -$0.10 derived: net income ÷ weighted average shares · filed 2020-03-27 | -$0.16 derived: net income ÷ weighted average shares · filed 2020-03-27 | -$0.23 derived: net income ÷ weighted average shares · filed 2020-03-27 | -$0.35 10-K · filed 2020-03-27 | |
| 2018-09-30 | -$0.07 10-Q · filed 2018-11-09 | -$0.14 derived: net income ÷ weighted average shares · filed 2019-11-12 | -$0.25 10-Q · filed 2019-11-12 | -$0.31 derived: net income ÷ weighted average shares · filed 2019-11-12 | |
| 2018-06-30 | -$0.07 10-Q · filed 2019-11-12 | -$0.09 10-Q · filed 2018-08-09 | -$0.18 10-Q · filed 2019-08-08 | -$0.24 derived: net income ÷ weighted average shares · filed 2019-11-12 | -$1.86 derived: net income ÷ weighted average shares · filed 2019-11-12 |
| 2018-03-31 | -$0.09 10-Q · filed 2019-05-10 | -$0.17 derived: net income ÷ weighted average shares · filed 2019-11-12 | -$1.80 derived: net income ÷ weighted average shares · filed 2019-11-12 | -$1.89 derived: net income ÷ weighted average shares · filed 2019-11-12 | |
| 2017-12-31 | -$0.08 derived: net income ÷ weighted average shares · filed 2019-02-26 | -$1.72 derived: net income ÷ weighted average shares · filed 2019-02-26 | -$1.81 derived: net income ÷ weighted average shares · filed 2019-02-26 | -$1.89 10-K · filed 2019-02-26 | |
| 2017-09-30 | -$1.68 10-Q · filed 2018-11-09 | -$1.77 derived: net income ÷ weighted average shares · filed 2018-11-09 | -$1.84 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | -$0.07 10-Q · filed 2018-08-09 | -$0.11 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | -$0.04 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |